CAR T-Cell Therapy for Multiple Myeloma Market Insights and Forecast till 2030
DelveInsight’s ‘CAR
T-Cell Therapy for Multiple Myeloma-Market Insights and Market Forecast-2030’
report delivers an in-depth understanding of the CAR T-Cell Therapy use for
Multiple Myeloma as well as the CAR T-Cell Therapy market trends for Multiple
Myeloma in the 6MM i.e., United States and EU5 (Germany, Spain, Italy, France
and the United Kingdom).
 |
| CAR T Cell therapy for Multiple Myeloma Market |
Multiple myeloma is a rare type of
cancer that develops in plasma cells. The patients diagnosed with Multiple
Myeloma, have cancer cells which are eventually overtake the healthy plasma
cells. This process depletes the body of much-needed white blood cells.
A cure for Multiple Myeloma currently doesn’t
exist. However, significant research is making progressive leaps toward a
treatment that eliminates the cancer entirely. None of the CAR T-cell therapies
gained approval for Myeloma, however some of the late-stage potential therapies
will impact the market in the near future.
Recent advancement in the upcoming therapies
for Myeloma treatment with the development of CAR-T therapies will allow for
greater availability of these approaches to patients. A number of new approaches
are being explored to better optimize cellular therapies in myeloma.
Combinations with immunomodulatory drugs and
checkpoint inhibitors may continue to enhance CAR T-cell activity, and clinical
trials of these combinations are underway. The global Multiple Myeloma market
is likely to be driven by the shift in the lifestyle of consumers and growing
cases of plasma cancer across the globe. The rising penetration of cancer drugs
including potential CAR-T therapies with their upcoming launch is expected to bode
well for the growth of the global Multiple Myeloma market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the
United Kingdom)
Study Period: 2017–2030
Multiple Myeloma Disease
Understanding, Use of CAR-T Cell Therapies and Treatment Algorithm
Multiple Myeloma Overview and use of CAR-T
Cell Therapies Overview
Chimeric antigen receptor (CAR) T-cell
therapy involves genetic modification of patient’s autologous T-cells to
express a CAR, specific for a tumor antigen, followed by ex vivo cell expansion
and re-infusion back to the patient. CAR T-cells are the fusion proteins of a
selected single-chain fragment variable from a specific monoclonal antibody and
one or more T-cell receptor intracellular signalling domains.
A CAR combines antigen-binding domains-most
commonly, a single-chain variable fragment (scFv) derived from the variable
domains of antibodies with the signalling domains of the TCR chain and
additional costimulatory domains from receptors, such as CD28, OX40, and CD137
(Morgenstern & Irwin, 2019).
T-cell genetic modification may occur either
via viral-based gene transfer methods or non-viral methods, such as DNA-based
transposons, CRISPR/Cas9 technology, zinc finger nuclease (ZFN), transcription
activator-like effector nuclease (TALEN), or direct transfer of in vitro
transcribed-mRNA by electroporation.
Multiple myeloma is a malignant proliferative
disease of plasma cells. Clonal plasma cells producing immunoglobulin,
proliferate and accumulate abnormally within the bone marrow, leading to
hematopoietic insufficiency and lytic bone lesions. According to WHO, in 2018,
159,985 incident cases of multiple myeloma were reported in the world.
Though some substantial improvement measures
have been implemented in the therapy of multiple myeloma, this disease still
remains a highly incurable fatal hematopoietic malignancy for which potentially
curative and safer novel treatments are required.
Multiple Myeloma Treatment
It covers the details of conventional and current
therapy available in the Multiple Myeloma market for the treatment of the
condition. It also provides the country-wise treatment guidelines and algorithm
across the United States and Europe.
The DelveInsight Multiple Myeloma CAR T-Cell
Therapy market report gives a thorough understanding of Multiple Myeloma by
including details such as disease definition, symptoms, causes,
pathophysiology, and diagnosis. It also provides treatment algorithms and
treatment guidelines for Multiple Myeloma in the US and Europe.
Browse full report: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-market
Multiple Myeloma CAR
T-Cell Therapy Chapters
CAR T-Cell Therapy chapter segment of the
Multiple Myeloma report encloses the detailed analysis of Multiple Myeloma
marketed Therapy and late stage (Phase-III and Phase-II) pipeline drugs based
on CAR-T Cell therapies.. It also helps to understand the CAR T-Cell Therapy
based clinical trial details, expressive pharmacological action, agreements and
collaborations, approval and patent details, advantages and disadvantages of
each included Therapy and the latest news and press releases for the treatment
of Multiple Myeloma.
CAR T-Cell Based Emerging Therapies for
Multiple Myeloma
1. bb2121: Bluebird bio/Celgene
bb2121 (also known as anti-BCMA CAR T-cells)
is under development by Celgene (a BMS company) in collaboration with Bluebird
bio. It is in phase III stage of development for the treatment of Multiple
Myeloma.
Products detail in the report…
Multiple Myeloma CAR
T-Cell Therapy Market Outlook
The Multiple Myeloma CAR T-Cell Therapy
market outlook of the report helps to build the detailed comprehension of the
historic, current and forecasted Multiple Myeloma CAR T-Cell Therapy market
trends by analyzing the impact of current therapies on the market, unmet needs,
drivers and barriers and demand of better technology.
This segment gives a thorough detail of
Multiple Myeloma CAR T-Cell Therapy market trend of each marketed Therapy and
late-stage pipeline therapy by evaluating their impact based on annual cost of
therapy, inclusion and exclusion criteria’s, mechanism of action, compliance
rate, growing need of the market, increasing patient pool, covered patient
segment, expected launch year, competition with other therapies, brand value,
their impact on the market and view of the key opinion leaders. The calculated
market data are presented with relevant tables and graphs to give a clear view
of the market at first sight.
·
According
to DelveInsight, Multiple Myeloma CAR T-Cell Therapy market in 6MM is expected
to change in the study period 2017–2030
·
Market
Size of CAR T-Cell Therapy for Multiple Myeloma in the 6MM is expected to be
USD 3,766.4 Million in 2030
·
Owing
to the launch of upcoming therapies, market size shall increase during forecast
period (2020-2030)
·
Among
the EU-5 countries, the Germany, France, Italy accounts for highest market size
for CAR T-Cell Therapy for Multiple Myeloma followed by UK and Spain
Multiple Myeloma CAR
T-Cell Therapy Uptake
This section focuses on the rate of uptake of
the potential CAR T-Cell Therapy expected to get launched in the market during
the study period 2017–2030. The analysis covers Multiple Myeloma market uptake
by CAR T-Cell therapies; patient uptake by therapies; and sales of each
therapy.
This helps in understanding the CAR T-Cell
Therapy with the most rapid uptake, reasons behind the maximal use of new CAR
T-Cell Therapy and allows the comparison of the therapies on the basis of
market share and Size which again will be useful in investigating factors
important in market uptake and in making financial and regulatory decisions.
CAR T-Cell Therapy
Pipeline Development Activities for Multiple Myeloma
The report provides insights into different
therapeutic candidates in Phase II, and Phase III stage. It also analyses CAR
T-Cell Therapy key players involved in developing targeted therapeutics for
Multiple Myeloma.
Pipeline Development Activities
The report covers the detailed information of
collaborations, acquisition and merger, licensing and patent details for
emerging CAR T-Cell Therapy for Multiple Myeloma.
Reimbursement Scenario in Multiple Myeloma
CAR T-Cell Therapy
Approaching reimbursement proactively can
have a positive impact both during the late stages of product development and
well after product launch. In report we take reimbursement into consideration
to identify economically attractive indications and market opportunities. When
working with finite resources, the ability to select the markets with the
fewest reimbursement barriers can be a critical business & price strategy.
KOL- Views
To keep up with current market trends, we
take KOLs and SME’s opinion working in CAR T-Cell Therapy for Multiple Myeloma
domain through primary research to fill the data gaps and validate our
secondary research. Their opinion helps to understand and validate current and
emerging therapies treatment patterns or Multiple Myeloma market trend. This
will support the clients in potential upcoming novel CAR T-Cell Therapy for
Multiple Myeloma treatment by identifying the overall scenario of the market
and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive & Market
Intelligence analysis of the Multiple Myeloma CAR T-Cell Therapy Market by
using various Competitive Intelligence tools that includes – SWOT analysis,
PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc.
The inclusion of the analysis entirely depends upon the data availability.
Request for free sample
pages: https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-multiple-myeloma-market
Scope of the Report
·
The
report covers the descriptive overview of Multiple Myeloma, explaining its
causes, signs and symptoms, pathophysiology and currently available CAR T-Cell
Therapy for Multiple Myeloma.
·
Comprehensive
insight has been provided into the CAR T-Cell Therapy for Multiple Myeloma
treatment in the 6MM
·
Additionally,
an all-inclusive account of both the current and emerging CAR T-Cell Therapy
for Multiple Myeloma are provided, along with the assessment of new therapies,
which will have an impact on the current treatment landscape
·
A
detailed review of Multiple Myeloma CAR T-Cell Therapy market; historical and
forecasted is included in the report, covering drug outreach in the 6MM
·
The
report provides an edge while developing business strategies, by understanding
trends shaping and driving the global Multiple Myeloma CAR T-Cell Therapy
market
Report Highlights
·
In
the coming years, Multiple Myeloma CAR T-Cell Therapy market is set to change
due to the rising awareness of the disease, and incremental healthcare spending
across the world; which would expand the Size of the market to enable the drug
manufacturers to penetrate more into the market
·
The
companies and academics are working to assess challenges and seek opportunities
that could influence CAR T-Cell Therapy R&D activities for Multiple
Myeloma. The therapies under development are focused on novel approaches to treat/improve
the disease condition
·
Major
players are involved in developing CAR T-Cell Therapy for Multiple Myeloma.
Launch of emerging therapies, will significantly impact the Multiple Myeloma
CAR T-Cell Therapy market
·
A
better understanding of disease pathogenesis will also contribute to the
development of novel CAR T-Cell Therapies for Multiple Myeloma
·
Our
in-depth analysis of the pipeline assets across different stages of development
(Phase III and Phase II), different emerging trends and comparative analysis of
pipeline products with detailed clinical profiles, key cross-competition,
launch date along with product development activities will support the clients
in the decision-making process regarding their therapeutic portfolio by
identifying the overall scenario of the research and development activities
Reasons to buy
·
The
report will help in developing business strategies by understanding trends
shaping and driving the Multiple Myeloma CAR T-Cell Therapy market
·
To
understand the future market competition in the Multiple Myeloma CAR T-Cell
Therapy market and Insightful review of the key market drivers and barriers
·
Organize
sales and marketing efforts by identifying the best opportunities for CAR
T-Cell Therapy for Multiple Myeloma in US and Europe (Germany, Spain, Italy,
France and United Kingdom).
·
Identification
of strong upcoming players in market will help in devising strategies that will
help in getting ahead of competitors
·
Organize
sales and marketing efforts by identifying the best opportunities for Multiple
Myeloma CAR T-Cell Therapy market
·
To
understand the future market competition in the Multiple Myeloma CAR T-Cell
Therapy market
What is CAR T-Cell Therapy?
Chimeric Antigen Receptor (CAR) T-cell
therapy is a technique that involves genetic modification of patient’s
autologous T-cells for CAR expression, specific for a tumor antigen, followed
by ex-vivo cell expansion and re-infusion back to the patient.
What is forecasted CAR T-Cell Therapy for
Multiple Myeloma market size in 2030?
Market Size of CAR T-Cell Therapy for
Multiple Myeloma in the 6MM is expected to be USD 3,766.4 Million in 2030.
What are the CAR T-Cell Therapy for
Multiple Myeloma market drivers?
Advancements in technology, Increased
collaborations and acquisitions and Competition among biotech and pharma giants
are the market drivers of CAR T-Cell Therapy for Multiple Myeloma.
What are the CAR T-Cell Therapy for
Multiple Myeloma market barriers?
Adverse events and toxicity concerns,
Regulatory challenges and High cost and low accessibility are the market
barriers of CAR
T-Cell Therapy for Multiple Myeloma.
How many companies are developing drugs
for CAR
T-Cell Therapy for Multiple Myeloma?
Celgene Corporation, Janssen Research &
Development, Poseida Therapeutics, MolMed S.p.A, Cartesian Therapeutics,
CARsgen Therapeutics, Precision BioSciences
What are the drugs involved in CAR T-Cell Therapy for Multiple myeloma?
bb2121, JNJ-68284528 (LCAR-B38M), P-BCMA-101,
CAR-CD44v6, JCARH125, Descartes-08, CT053, PBCAR269A.
What is Multiple Myeloma?
Multiple Myeloma is a rare type of cancer
that develops in plasma cells. The patients diagnosed with Multiple Myeloma
have cancer cells that eventually supersede the healthy plasma cells. This
process exhausts the much-needed white blood cells in the body.
View full report @https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-market
Comments
Post a Comment